A new sirolimus-coated balloon (SCB) is noninferior to a paclitaxel-coated balloon (PCB) in patients with in-stent restenosis (ISR) at 9-month follow-up and similar 1-year clinical events, a new study shows.
The U.S. Food and Drug Administration balances patient safety, clinician decision-making and regulatory flexibility in their approval process for medical devices but also must safely and efficiently continue to bring new technologies and innovations to patients, two recent viewpoint articles point out.
Study findings published in Feb 10 edition of JACC: Cardiovascular Interventions detail the effectiveness of transapical transcatheter mitral valve replacement (TMVR) following failed transcatheter edge-to-edge repair (M-TEER).
Conclusions drawn from a recent study have pointed to the potential of a novel carotid stent system that could benefit patients at high risk of complications from carotid endarterectomy (CEA).
Coronary stent underexpansion (SU) remains a major challenge in percutaneous coronary intervention (PCI), increasing restenosis and thrombosis risks, according to a new review that proposes an intravascular imaging (IVI)-guided algorithm to systematically optimize stent expansion and improve patient outcomes.
Tricuspid regurgitation (TR) disease stage may influence survival outcomes following tricuspid transcatheter edge-to-edge repair (T-TEER), according to a new analysis of 1-year follow-up data that suggests individuals with intermediate TR may receive the most substantial treatment benefits.
In patients with a history of stroke, salt substitution is safe, and the risks of death and recurring stroke are reduced, a new cluster trial shows.
Among individuals in sexual minority (SM) groups in the US, those with unfavorable social determinants of health (SDOH) profiles have worse cardiovascular health (CVH) scores and are at higher risk for cardiovascular mortality compared with heterosexual individuals, a new study shows.
Mechanical surgical aortic valve replacement (AVR) is independently associated with significant survival benefits compared with bioprosthetic AVR in patients aged 60 years and younger, a real-world analysis shows.
Bailey G. Salimes, CRTonline.org
Natalie Morrison, CRTonline.org
Will Chu, CRTonline.org
Nathan Gray, CRTonline.org
Michael Mahmoudi, MD - D van Ginkel, et al.; TAVI. NEJM 2025; 392:438-449
Michael Mahmoudi, MD - S Jolly, et al.; NEJM 2025; 392:643-652
Michael Mahmoudi, MD - S Jolly et al.; NEJM 2025; 392:633-642
Michael Mahmoudi, MD - P Generreux, et al.; NEJM 2025; NEJM 2025; 392:217-227
What is your opinion on the collection of biomarkers after PCI?
Routine biomarker monitoring after PCI is not necessary.
At least one biomarker measurement after PCI is important.
Biomarker collection should be limited to patients with complicated PCI.
Kalyan R. Chitturi, Ryan Wallace, Abhishek Chaturvedi, Ilan Merdler, Nauman Khalid, Brian C. Case, Hayder D. Hashim, Itsik Ben-Dor, Toby Rogers and Ron Waksman
Elena Dipietro, Giuliano Costa, Mariachiara Calì, Orazio Strazzieri, Silvia Crescenzia Motta, Valentina Frittitta, Alessandro Comis, Sofia Sammartino, Luigi La Rosa, Carmelo Sgroi, Wanda Deste, Pierfrancesco Veroux, Salvatore Lentini, Maria Cristina Inserra, Maria Teresa Cannizzaro, Valeria Garretto, Corrado Tamburino and Marco Barbanti
Elsa Hebbo, Madeleine Barker, Daniel A. Gold, Malika Elhage Hassan, Mariem Sawan, Tanveer Rab, William J. Nicholson, Michael E. Halkos, Wissam A. Jaber and Pratik B. Sandesara
Soban Ahmad, Muhammad Junaid Ahsan, Morgan Newlun, Mitchell Sand, Anan Abu Rmilah, Amman Yousaf, Muhammad Asim Shabbir, Shahbaz A. Malik and Andrew M. Goldsweig
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details